Cargando…
FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma
BACKGROUND: Metastatic renal cell carcinoma has a poor prognosis and an intrinsic resistance to standard treatment. Sunitinib is an oral receptor tyrosine kinase inhibitor that has been used as a first-line targeted therapy in metastatic renal cell carcinoma. While computed tomography (CT) is curren...
Autores principales: | Horn, Kevin P., Yap, Jeffrey T., Agarwal, Neeraj, Morton, Kathryn A., Kadrmas, Dan J., Beardmore, Britney, Butterfield, Regan I., Boucher, Kenneth, Hoffman, John M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4558962/ https://www.ncbi.nlm.nih.gov/pubmed/26335224 http://dx.doi.org/10.1186/s40644-015-0049-x |
Ejemplares similares
-
Second-line sunitinib for Chinese patients with advanced gastrointestinal stromal tumor: 37.5 mg schedule outperformed 50 mg schedule in adherence and prognosis
por: Zhang, Chenli, et al.
Publicado: (2021) -
Myelosuppression by sunitinib is flt-3 genotype dependent
por: van Erp, N P, et al.
Publicado: (2010) -
Frovatriptan 2.5 mg plus dexketoprofen (25 mg or 37.5 mg) in menstrually related migraine. Subanalysis from a double-blind, randomized trial
por: Allais, G, et al.
Publicado: (2015) -
Comparative pharmacokinetics between two tablets of tramadol 37.5 mg/acetaminophen 325 mg and one tablet of tramadol 75 mg/acetaminophen 650 mg for extended-release fixed-dose combination
por: Kim, Hyun Chul, et al.
Publicado: (2022) -
Early Monitoring Antiangiogenesis Treatment Response of Sunitinib in U87MG Tumor Xenograft by (18)F-FLT MicroPET/CT Imaging
por: Bao, Xiao, et al.
Publicado: (2014)